These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Ortho Evra/Evra versus oral contraceptives: follicular development and ovulation in normal cycles and after an intentional dosing error. Pierson RA; Archer DF; Moreau M; Shangold GA; Fisher AC; Creasy GW Fertil Steril; 2003 Jul; 80(1):34-42. PubMed ID: 12849799 [TBL] [Abstract][Full Text] [Related]
10. A comparative and pooled analysis of the safety and tolerability of the contraceptive patch (Ortho Evra/Evra). Sibai BM; Odlind V; Meador ML; Shangold GA; Fisher AC; Creasy GW Fertil Steril; 2002 Feb; 77(2 Suppl 2):S19-26. PubMed ID: 11849632 [TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and pharmacodynamics of a transdermal contraceptive patch and an oral contraceptive. Devineni D; Skee D; Vaccaro N; Massarella J; Janssens L; LaGuardia KD; Leung AT J Clin Pharmacol; 2007 Apr; 47(4):497-509. PubMed ID: 17389559 [TBL] [Abstract][Full Text] [Related]
13. Contraceptive efficacy of oral and transdermal hormones when co-administered with protease inhibitors in HIV-1-infected women: pharmacokinetic results of ACTG trial A5188. Vogler MA; Patterson K; Kamemoto L; Park JG; Watts H; Aweeka F; Klingman KL; Cohn SE J Acquir Immune Defic Syndr; 2010 Dec; 55(4):473-82. PubMed ID: 20842042 [TBL] [Abstract][Full Text] [Related]
14. Transdermal ethinylestradiol/norelgestromin: a review of its use in hormonal contraception. Goa KL; Warner GT; Easthope SE Treat Endocrinol; 2003; 2(3):191-206. PubMed ID: 15966567 [TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic overview of ethinyl estradiol dose and bioavailability using two transdermal contraceptive systems and a standard combined oral contraceptive. Hofmann B; Reinecke I; Schuett B; Merz M; Zurth C Int J Clin Pharmacol Ther; 2014 Dec; 52(12):1059-70. PubMed ID: 25295716 [TBL] [Abstract][Full Text] [Related]
16. The effect of efavirenz on the pharmacokinetics of an oral contraceptive containing ethinyl estradiol and norgestimate in healthy HIV-negative women. Sevinsky H; Eley T; Persson A; Garner D; Yones C; Nettles R; Krantz K; Bertz R; Zhang J Antivir Ther; 2011; 16(2):149-56. PubMed ID: 21447863 [TBL] [Abstract][Full Text] [Related]
17. Assessment of compliance with a weekly contraceptive patch (Ortho Evra/Evra) among North American women. Archer DF; Bigrigg A; Smallwood GH; Shangold GA; Creasy GW; Fisher AC Fertil Steril; 2002 Feb; 77(2 Suppl 2):S27-31. PubMed ID: 11849633 [TBL] [Abstract][Full Text] [Related]
18. Extended use of transdermal norelgestromin/ethinyl estradiol: a randomized trial. Stewart FH; Kaunitz AM; Laguardia KD; Karvois DL; Fisher AC; Friedman AJ Obstet Gynecol; 2005 Jun; 105(6):1389-96. PubMed ID: 15932834 [TBL] [Abstract][Full Text] [Related]
19. Effect of laropiprant, a PGD2 receptor 1 antagonist, on estradiol and norgestimate pharmacokinetics after oral contraceptive administration in women. Schwartz JI; Liu F; Wang YH; Pramanik B; Johnson-Levonas AO; Gutierrez MJ; Lai E; Wagner JA Am J Ther; 2009; 16(6):487-95. PubMed ID: 19940609 [TBL] [Abstract][Full Text] [Related]
20. Comparison of a transdermal contraceptive patch with a newly sourced adhesive component versus EVRA patch: A double-blind, randomized, bioequivalence and adhesion study in healthy women. Parasrampuria DA; Vaughan S; Ariyawansa J; Swinnen A; Natarajan J; Rasschaert F; Massarella J; Fonseca S Contraception; 2020 Apr; 101(4):276-282. PubMed ID: 31935382 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]